New trial available: Click on any alert below and access our regulatory alerts and get timely notifications sent to your inbox for 7 days.
22nd March 2023
20th March 2023
20th March 2023
17th March 2023
23rd February 2023
Thailand: A bill to regulate cannabis will not be passed during the current parliamentary session and will have to be addressed again in the new parliament after the 7th May elections, press reports. The Bhumjaithai Party, which has spearheaded cannabis legalisation efforts, say they will resubmit the bill in the next parliament. The government removed cannabis from its narcotics list last June but has not passed legislation to regulate it. Cannabis legalisation has become a hot-button issue for the upcoming election.
23rd February 2023
India: Chief parliamentary secretary Sunder Singh Thakur said yesterday that the state government of Himachal Pradesh was working to legalise the cultivation of cannabis for medicinal and industrial purposes, press reports.
21st February 2023
Philippines: Former House speaker Pantaleon Alvarez of the minority Party for Democratic Reform has filed a bill in the House of Representatives to remove cannabis and its derivatives from the list of dangerous drugs and decriminalise its cultivation and possession. The bill is pending in the Dangerous Drugs Committee.
21st February 2023
Thailand: The Democrat Party, a member of the government coalition that currently holds 51 of 500 seats in the House of Representatives, is vowing to re-criminalise recreational cannabis and support medical use only in its campaign for the May election, press reports. The stance represents a break from the party’s pro-cannabis coalition partner, the Bhumjaithai Party. Cannabis legalisation has become a hot-button issue for the upcoming election and its fate could hang on election results.
13th February 2023
6th February 2023
1st February 2023
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.